GlyMab platform – Talk Bio

Actionable Insights Powered by AI

Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings

Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies